Tandem Diabetes Care INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Tandem Diabetes Care announced its first quarter 2026 financial results, showing increased sales and improved gross margin, but a net loss.
NASDAQ
Tandem Diabetes Care reports increased sales and improved gross margins for Q3 and YTD 2025, but a significant rise in year-to-date net loss driven by one-time expenses.
NASDAQ
Tandem Diabetes Care reported a wider net loss in the second quarter of 2025, driven by significant litigation settlement expenses and increased R&D investments, despite an increase in sales.
NASDAQ
Tandem Diabetes Care's Q1 2025 revenue increased year-over-year, but a significant charge related to the AMF Medical acquisition contributed to a larger net loss.
NASDAQ
10-Q: Tandem Diabetes Care Reports Strong Third Quarter Revenue Growth Driven by Increased Pump Shipments
Tandem Diabetes Care's Q3 2024 results show a significant increase in revenue and pump shipments compared to the same period last year, despite ongoing operating losses.
NASDAQ
Tandem Diabetes Care's second quarter 2024 results show increased sales but a net loss, reflecting ongoing investments and market shifts.
NASDAQ
Tandem Diabetes Care's first quarter 2024 results show a revenue increase year-over-year, but the company still reports a net loss.